作者
Benjamin D. Ehst,Richard Bruce Warren,Chih-ho Hong,Dong Hun Lee,Andrei I. Metelitsa,Sebastian Volc,M. Tauber,Farzaneh Safavimanesh,Ann‐Marie Tindberg,Linda Stein Gold
摘要
Results (cont.)Clinician-reported outcomes Investigator Global Assessment -Atopic Hand Ezema (IGA-AHE) • The primary endpoint was met at Week 16, with 40.0% of patients who received tralokinumab achieving IGA-AHE 0/1 compared with 10.6% of patients who received placebo (treatment difference [95% CI]: 29.7% [19.0, 40.4], P<0.001; Figure 1;Table 1) • Response rates continued to improve through Week 32, with 57.9% (77/133) of patients continuing tralokinumab achieving IGA-AHE 0/1 (as observed) Hand Eczema Severity Index (HECSI) • The number of patients achieving HECSI-50, HECSI-75 or HECSI-90 was significantly greater for tralokinumab compared with placebo at Week 16 (Table 1) • 41.7% of patients who received tralokinumab achieved HECSI-90 compared with 10.9% of patients who received placebo (treatment difference [95% CI]: 30.8% [20.0, 41.5], P<0.001); Figure 2; Table 1) • Further improvements were observed through Week 32 on all HECSI outcomes Objective • To evaluate the 32-week efficacy and safety of tralokinumab compared with placebo in patients with AD and moderate-to-severe hand involvement, who were candidates for systemic therapy Abbreviations AD, atopic dermatitis; AE, adverse event; AHE, atopic hand eczema; CI, confidence interval; DLQI, Dermatology Quality of Life Index; HECSI, Hand Eczema Severity Index; HESCI-50/-75/-90, 50%/75%/90% decrease in HESCI; HEIS, Hand Eczema Impact Scale; HESD, Hand Eczema Symptom Diary; IGA-AHE, Investigator Global Assessment-atopic hand eczema; LOCF, last observation carried forward; MI, multiple imputation; n, number of patients with recorded observation; N, number of patients in indicated treatment set; NRI, non-responder imputation; OC, observed cases; Q2W, every 2 weeks; TCI, topical calcineurin inhibitor; TCS, topical corticosteroid.